Merck KGaA (XSWX:MER) Accounts Payable: CHF1,938 Mil (As of Mar. 2026)


XSWX:MER Merck KGaA XSWX:MER
81 GF Score
Price CHF132.80
GF Value CHF125.76
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Accounts Payable?

Merck KGaA XSWX:MER 81 Accounts Payable is CHF1,938 Mil as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 81/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review.

Merck KGaA's Accounts Payable for the quarter that ended in Mar. 2026 was CHF1,938 Mil.

Merck KGaA's quarterly Accounts Payable declined from Sep. 2025 (CHF1,802 Mil) to Dec. 2025 (CHF1,327 Mil) but then increased from Dec. 2025 (CHF1,327 Mil) to Mar. 2026 (CHF1,938 Mil).

Merck KGaA's annual Accounts Payable declined from Dec. 2023 (CHF1,669 Mil) to Dec. 2024 (CHF1,402 Mil) and declined from Dec. 2024 (CHF1,402 Mil) to Dec. 2025 (CHF1,327 Mil).

Merck KGaA Accounts Payable Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Accounts Payable Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,604.73 1,575.04 1,669.24 1,402.29 1,326.92

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,998.37 1,838.38 1,801.50 1,326.92 1,937.76
XSWX:MER
81GF Score
Merck KGaA XSWX:MER
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF1,938 Mil mean?
Merck KGaA (XSWX:MER) has a Accounts Payable of CHF1,938 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Accounts Payable too high?
Merck KGaA's current Accounts Payable is CHF1,938 Mil. Overall, Merck KGaA has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Accounts Payable compare to ZTS and UTHR?
Merck KGaA's Accounts Payable of CHF1,938 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Merck KGaA and its competitors. Merck KGaA's current Accounts Payable is CHF1,938 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Accounts Payable of CHF1,938 Mil. The stock's GF Value™ is CHF125.76, compared to a current price of CHF132.80 — trading 5.6% above its estimated fair value. The current Accounts Payable is CHF1,938 Mil. Merck KGaA's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Accounts Payable is CHF1,938 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of CHF132.80 is trading 5.6% above its estimated GF Value™ of CHF125.76.

Key valuation signals for XSWX:MER:

  • Accounts Payable: CHF1,938 Mil
  • GF Value™: CHF125.76 vs. price of CHF132.80 (5.6% above fair value)
  • GF Score™: 81/100 with 9 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
81GF Score

Get the complete analysis for XSWX:MER

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF132.80
Price
CHF125.76
GF Value